戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uld be ameliorated by blocking the adenosine A1 receptor.
2 ed by PD81723, an allosteric enhancer of the A1 receptor.
3 y DPCPX, indicating a prominent role for the A1 receptor.
4 ow are mediated by adenosine but not via the A1 receptor.
5 n of the A2A receptor on the neuroprotective A1 receptor.
6 that produced by activation of the adenosine A1 receptor.
7 y formed adenosine can chaperone its cognate A1 receptor.
8 ffinity indistinguishable from the wild-type A1 receptor.
9 indings were recapitulated for the wild-type A1 receptor.
10 , metabotropic glutamate mGlu5 and adenosine A1 receptors.
11 ells showed enhanced responses to M2 but not A1 receptors.
12  rescued presynaptic inhibition by adenosine A1 receptors.
13 vealed greater A2B selectivity over A2A than A1 receptors.
14 adenosine (CPA) it appears to be mediated by A1 receptors.
15 thanol is mediated through myocyte adenosine A1 receptors.
16 y C fibre terminals through an activation of A1 receptors.
17 appears to be due to activation of adenosine A1 receptors.
18 stimulate PRL release in vitro by activating A1 receptors.
19 hypoxia induces dilatation only by acting on A1 receptors.
20 nglia, probably by activation of presynaptic A1 receptors.
21 tion of cAMP formation through activation of A1 receptors.
22 amidal neurons via activation of presynaptic A1 receptors.
23 nd/or A2B but excluding the participation of A1 receptors.
24 A binding could be attributed to labeling of A1 receptors.
25 tion through activation of central adenosine A1 receptors.
26 ogeneous activation of presynaptic adenosine A1 receptors.
27 ulsant acting on excitatory synapses through A1 receptors.
28 ive consequences through a pathway involving A1 receptors.
29  tonically inhibited by adenosine acting via A1 receptors.
30 siently be provoked after blocking adenosine A1 receptors.
31 ciency was significantly reduced by blocking A1-receptors.
32 dent on adenosine-induced PKC activation via A1-receptors.
33 ateral RA had significantly higher adenosine A1 receptor (2.7+/-1.7-fold; P<0.01) and GIRK4 (1.7+/-0.
34 , Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-
35                                    Adenosine A1 receptor (A1-AdoR) function in rat ventricles has pre
36 retic action of a highly selective adenosine A1 receptor (A1AdoR) antagonist, 1,3-dipropyl-8-[2-(5,6-
37 esis that a partial agonist of the adenosine A1 receptor (A1AdoR) may cause a greater attenuation of
38 is study, we targeted the cochlear adenosine A1 receptor (A1AR) by trans-tympanic injections of the a
39    In this study, we show that the adenosine A1 receptor (A1AR) protects against cisplatin ototoxicit
40                                    Adenosine A1 receptor (A1AR) subtype present on renal proximal tub
41           Allosteric modulation of adenosine A1 receptors (A1ARs) offers a novel therapeutic approach
42  of A1 receptor signaling using an adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,3-dimethyl
43  cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CDC42-depend
44                                The adenosine A1 receptor (A1R) is a key mediator of the neuroprotecti
45 activity through activation of the adenosine A1 receptor (A1R), resulting in antinociception and high
46  synapses resulting in an enhanced adenosine A1 receptor (A1R)-dependent protective tone despite lowe
47 ate adenosine concentration and/or adenosine A1 receptors (A1R) in the brain.
48 s a neuromodulator acting through inhibitory A1 receptors (A1Rs) and facilitatory A2ARs, which have s
49  The suppression was mediated by presynaptic A1 receptors (A1Rs) because it was blocked by a selectiv
50          Activation of presynaptic adenosine A1 receptors (A1Rs) causes substantial synaptic depressi
51                                    Adenosine A1 receptors (A1Rs) in human and rodent brains can be vi
52 Because very little is known about adenosine A1 receptors (A1Rs) in the spinal cord, we determined th
53 hippocampal neurons, activation of adenosine A1 receptors (A1Rs) or GABA(B) receptors on synaptic ter
54 n mice by increasing activation of adenosine A1 receptors (A1Rs).
55 rosynaptic plasticity; blockade of adenosine A1 receptors abolished it.
56 rosynaptic plasticity: blockade of adenosine A1 receptors abolished weight dependence, while increase
57                                    Adenosine A1 receptor activation also impaired the expression of b
58 fect of acupuncture is mediated by adenosine A1 receptor activation at the acupuncture point, we here
59       The inhibitory modulation of adenosine A1 receptor activation by hydroxylamine suggests the pre
60                                    Adenosine A1 receptor activation depresses excitatory transmission
61                                    Adenosine A1 receptor activation dose-dependently and selectively
62                          However, endogenous A1 receptor activation during cortical seizures in vivo
63      Given the central role demonstrated for A1 receptor activation in determining synaptic amplitude
64 d excitatory neurotransmission via adenosine A1 receptor activation in spinal cord slices from wild-t
65  of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhibition with
66 nal efficacy and therefore the heterogeneous A1 receptor activation seen in the mature neocortex appe
67   Adenosine elicits cardioprotection through A1-receptor activation.
68 mical property of dipole and selects against A1 receptor activity, generated a correlated final model
69 we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ERalpha target and a regul
70  potential glucagon inhibitor, the adenosine A1 receptor (Adora1), is gradually diminished in alpha-c
71 e thought to require activation of adenosine A1 receptors (adorA1Rs) and release of transmitter molec
72 te receptor antagonist MK-801; the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC
73                                          The A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (CC
74                                The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC
75                                 However, the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine and
76 stantial increase in CoRCF and CoVC, but the A1 receptor agonist 2-chloro-N6-cyclopentyladenosine had
77 ) receptor agonist baclofen or the adenosine A1 receptor agonist 2-chloroadenosine, short-term synapt
78     These data are consistent with adenosine A1 receptor agonist actions on REM sleep mediated throug
79 or sodium nitroprusside (SNP), the adenosine A1 receptor agonist CCPA (2-chloro-N6-cyclopentyladenosi
80  rats were treated IT with the selective Ado A1 receptor agonist cyclohexyladenosine (CHA) or vehicle
81     Intrastriatal microinfusion of adenosine A1 receptor agonist N6-cyclohexyladenosine (CHA) and ant
82 cholinergic neurons, the selective adenosine A1 receptor agonist N6-cyclohexyladenosine, administered
83 was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine and prevente
84                  Microinjection of adenosine A1 receptor agonist or an inhibitor of adenylyl cyclase
85                            Adenosine and the A1 receptor agonist R-phenylisopropyl adenosine (RPIA) r
86                        Similarly neither the A1 receptor agonist R-phenylisopropyladenosine (R-PIA),
87             Direct injection of an adenosine A1 receptor agonist replicated the analgesic effect of a
88 cked by exogenous adenosine or the selective A1 receptor agonist, 2-chloro-N6-cyclopentyl adenosine.
89 lices containing the PnOc incubated with the A1 receptor agonist, cyclohexaladenosine (10(-8) M).
90         The selective low efficacy adenosine A1 receptor agonist, GR190178 (30-1000 microg/kg i.v.),
91 nistration of the highly selective adenosine A1 receptor agonist, GR79236 (3-100 microg/kg) had a dos
92          N6-Cyclopentyl adenosine (adenosine A1 receptor agonist, Kd = 1 nmol/l) did not affect GLUT1
93 ystemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine (CHA; 0.3
94     In Experiment 1, the selective adenosine A1 receptor agonist, N6-cyclopentyladenosine (CPA), or s
95 ould be demonstrated only with the selective A1-receptor agonist 2-chloro-N6-cyclopentyladenosine and
96 denosine (CGS-21680; 100 nM), but not by the A1-receptor agonist N6-cyclopentyladenosine (CPA).
97 5.5% with SfA; P<0.001), CCPA (the adenosine A1-receptor agonist, 200 nmol/L) (24.9+/-4.5% versus 54.
98 cement of [3H]DPCPX binding by the selective A1-receptor agonist, N6-p-sulfophenyladenosine (SPA), yi
99 ts of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV) function a
100                      The selective adenosine A1 receptor agonists 2-chloro-N6-cyclopentyladenosine (C
101                    Intrathalamic infusion of A1 receptor agonists directly reduces tremor, whereas ad
102 derable literature to suggest that adenosine A1 receptor agonists may have anti-nociceptive effects,
103 tric oxide synthase inhibitors and adenosine A1 receptor agonists.
104 lts support development of partial adenosine A1-receptor agonists for the treatment of chronic heart
105                       Therapy with adenosine A1-receptor agonists, however, is limited by undesirable
106 distributions that spanned those of both the A1 receptor agonized and antagonized conditions.
107                 Overexpressing the adenosine A1 receptor also led to increased protection against isc
108                                  Blockade of A1 receptors ameliorated the depression caused by adenos
109        Allosteric enhancers of the adenosine A1 receptor amplify signaling by orthosteric agonists.
110 eceptor, dopamine transporter, and adenosine A1 receptor and decreased adenosine A2A receptor express
111 ion was blocked in the presence of adenosine A1 receptor and GABAB receptor blockade.
112  were combined with homology modeling of the A1 receptor and in silico screening of an allosteric enh
113 A areas with highest expression of adenosine A1 receptor and its downstream GIRK (G protein-coupled i
114 (R)-phenylisopropyl]adenosine from rat brain A1 receptors and [3H]2-[p-(2-carboxyethyl)phenyl-ethylam
115 ments using [3H]cyclohexyladenosine to label A1 receptors and [3H]CGS 21680 to label A2A receptors.
116  produced up-regulation of central adenosine A1 receptors and created a state of opiate dependence, w
117 M, respectively, at the rat and cloned human A1-receptors and with 1800-fold (rat) and 2400-fold (hum
118 which was prevented by blockade of adenosine A1 receptors, and decreased expression of genes involved
119 racellular Ado, activation of inhibitory Ado A1 receptors, and decreased seizure generation, the desi
120 at is mediated mainly by adenosine acting on A1 receptors, and that the vasoconstrictor effects of sy
121 itive potassium (K(ATP)) channels, adenosine A1 receptors, and the effects of different levels of hal
122 ilocapnic HVR; (2) these impairments require A1 receptors; and (3) SF of OSA may exacerbate OSA via i
123 tor than in those cells expressing the human A1 receptor (ANOVA and posttest comparison, P<0.01).
124                          Moreover, adenosine A1 receptor antagonism had larger effects on theta respo
125 ac arrhythmias and seizures due to adenosine A1-receptor antagonism.
126 xogenous adenosine, or a selective adenosine A1 receptor antagonist (8-cyclopentyl-1, 3-dimethylxanth
127                                The adenosine A1 receptor antagonist 1,3-dipopylcyclopentylxanthine pr
128 0.9%) by systemic injection of the adenosine A1 receptor antagonist 8-CPT (2.5 mg kg(-1)) approximate
129 ly reversed in the presence of the adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthi
130                           Both the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
131 ibitor l-NAME (Group 1, n = 8) and adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
132                                The adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
133 s a mediator of IPC, the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
134              The concomitant presence of the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
135                                The selective A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
136                      The selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
137  the administration of a selective adenosine A1 receptor antagonist but not by a selective adenosine
138   Since the sleep-suppressing effects of the A1 receptor antagonist CPT were prevented following inhi
139 or administration of the selective adenosine A1 receptor antagonist dipropylcyclopentylxanthine (DPCP
140 arge induced by adenosine was blocked by the A1 receptor antagonist DPCPX (10 microM) but remained un
141 ould be inhibited by the selective adenosine A1 receptor antagonist DPCPX (300 microg/kg; P < 0.05).
142 fter administration of a selective adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropyl
143 .4 nM for antagonism of CPA by the adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropyl
144                                The adenosine A1 receptor antagonist DPCPX did not affect the resting
145 N6-cyclopentyladenosine and prevented by the A1 receptor antagonist N-0861.
146 acerebroventricular infusion of an adenosine A1 receptor antagonist produced a similar decrease in se
147             Here, we show that the adenosine A1 receptor antagonist rolofylline (KW-3902) is alleviat
148  Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospital
149 ble to that of BG9928, a selective adenosine A1 receptor antagonist that is currently in clinical tri
150 ropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist that is permeable to the blood br
151    Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.88 and is h
152 (4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the ot
153      In the search for a selective adenosine A1 receptor antagonist with greater aqueous solubility t
154  of SPWs in slices treated with an adenosine A1 receptor antagonist, a finding that links the present
155 y 1,3-dipropyl-8-cyclopentylxanthine, an Ado A1 receptor antagonist, but was unaffected by 3,7-dimeth
156  protein kinase A inhibitor and an adenosine A1 receptor antagonist.
157 nized by 8-phenyltheophylline (1 microM), an A1 receptor antagonist.
158 ed with either a glial toxin or an adenosine A1 receptor antagonist.
159 lfophenyl theophylline or with the selective A1-receptor antagonist 1,3-dipropyl, 8-cyclopentylxanthi
160 F and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response to loop di
161 is that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea, reduce th
162 ion were abolished or prevented by adenosine A1 receptor antagonists (50 mumol/L theophylline/1 mumol
163 ling, readily repeatable, and was blocked by A1 receptor antagonists and by adenosine deaminase, sugg
164     Pertinent to this, brief applications of A1 receptor antagonists immediately after theta stimulat
165 pargylxanthine (DMPX), but unaffected by the A1-receptor antagonists 8-cyclopentyl-1,3-dipropylxanthi
166 eizures, a known potential adverse effect of A1-receptor antagonists.
167             After microdialysis perfusion of A1 receptor antisense in the basal forebrain, spontaneou
168                    The increased activity at A1 receptors appeared to be attributable to the direct r
169 lic imidazoline antagonists of the adenosine A1 receptor are described.
170 se effects are mediated by A1 receptors, but A1 receptors are expressed in most brain regions, and di
171        These results indicate that adenosine A1 receptors are selectively upregulated during ethanol
172                                    Adenosine A1 receptor blockade abolished the protection provided b
173 ibition of nucleotide breakdown or adenosine A1 receptor blockade and reduced by apyrase inactivation
174                                        Thus, A1 receptor blockade enhances and A2a receptor blockade
175 d during P2X receptor blockade with NF279 or A1 receptor blockade with 1,3-dipropyl-8-cyclopentylxant
176                                    Adenosine A1 receptor blockade with 4.5 mg/kg DPCPX administered i
177 MPX on the induction of LTP during continued A1 receptor blockade with CPT.
178  effect on LTP induction was observed during A1 receptor blockade.
179 uate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal function in p
180 ability that were almost coincident with the A1 receptor blocked condition; however, mature synapses
181                                          The A1 receptor blocker DPCPX did not alter autoregulatory b
182 -1, 3-dipropylxanthine (DPCPX) (an adenosine A1 receptor blocker).
183 ed by microperfusing nephrons with adenosine A1 receptor blocker, A1-agonist, or 5'-nucleotidase inhi
184 RPV4 channel, GABAB, as well as an adenosine A1 receptor blocker.
185 us adenosine inhibited glutamate release via A1 receptors but only inhibited ATP release via A2-like
186        Many of these effects are mediated by A1 receptors, but A1 receptors are expressed in most bra
187 thway can be inhibited through activation of A1 receptors by adenosine.
188 ncreased activation of presynaptic adenosine A1 receptors by endogenous adenosine.
189                                              A1 receptors caused inhibition of both ATP and glutamate
190                                Activation of A1 receptors causes inhibition of adenylate cyclase, dec
191 maphorins signal through neuropilin-2/plexin-A1 receptor complexes on post-crossing commissural axons
192 ypothesis that changes in both adenosine and A1 receptor concentrations can capture changes in cognit
193 ctivity, we examined their action on several A1 receptor constructs, including (1) species variants,
194                                    Adenosine A1 receptor control of the homeostatic regulation of sle
195 the present work, we tested whether blocking A1 receptors could enhance the damage to DAergic and GAB
196 d subsequent heterologous desensitization of A1 receptors could occur, which might limit the cerebrop
197                 The K+ efflux resulting from A1-receptor-coupled KATP-channel activation facilitates
198                                    Since the A1 receptors decrease intracellular-free calcium, this w
199   Thus, enhancing adenosine's binding to the A1 receptor decreases hypoxic brain damage.
200 sults were not associated with variations in A1 receptor densities and may instead reflect regional a
201 middle-aged slices and thereby activates the A1 receptor-dependent LTP reversal effect.
202 oligodeoxynucleotide targeting the adenosine A1 receptor desensitized the animals to subsequent chall
203                          Furthermore, M2 and A1 receptors differentially use Galphai2 and Galphao and
204 s tested (cAMP, AMP, ADP, and ATP) activated A1 receptors directly at the concentrations tested (</=2
205 tions suggest that the upregulation of brain A1 receptors during ethanol withdrawal may represent a c
206 long-term exposure to caffeine did not alter A1 receptor expression at the acupuncture point.
207 e SAN structure, SAN function, and adenosine A1 receptor expression in control (n=17) and 4-month tac
208 affeine during adulthood increased adenosine A1 receptor expression in the NAc, but no other protein
209  anti-nociceptive actions required adenosine A1 receptor expression.
210 ucted to examine the importance of adenosine A1 receptors for the acquisition and expression of hippo
211  this response to adenosine, but deletion of A1 receptors from CA1 neurons had no effect, demonstrati
212                                  Deletion of A1 receptors from CA3 neurons abolished this response to
213 ht be attributable to the enhanced adenosine A1 receptor function on synaptic transmission, and the d
214 ateral RA regions with the highest adenosine A1 receptor/GIRK4 expression.
215      To inhibit K(ATP) channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n = 8), 5-hy
216 thiopyrimidines as selective human adenosine A1 receptor (hA1AR) agonists with tunable binding kineti
217                         However, blockade of A1 receptors had no effect on BOLD responses and did not
218      Antisense to the A1 receptor suppressed A1 receptor immunoreactivity but did not show any neurot
219    Conversely, over-expression of the cloned A1 receptor in CASMC increases adenosine- and CCPA-induc
220 nse oligonucleotides against the mRNA of the A1 receptor in the magnocellular cholinergic region of t
221 d we sought to explore the role of adenosine A1 receptors in a model of trigeminovascular nociceptive
222               Stimulation of renal adenosine A1 receptors in animal models has resulted in a signific
223 on of emotional (fear) memories by acting on A1 receptors in brain regions underlying fear conditioni
224                               The density of A1 receptors in cerebral cortex was significantly increa
225 in barrier, we examine the role of adenosine A1 receptors in mediating cortical blood flow and metabo
226    Our results demonstrate a novel action of A1 receptors in modulating spinal motor activity.
227  vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis and for A
228 he concentrations of adenosine and adenosine A1 receptors in specific regions of the brain.
229 ector to focally delete endogenous adenosine A1 receptors in the hippocampus.
230 evel but not of K(ATP) channels or adenosine A1 receptors in the preconditioning effects of CSD.
231 ence supporting the involvement of adenosine A1 receptors in the regulation of the response of the ci
232 HVR), and investigated the role of adenosine A1 receptors in these SF effects in conscious adult male
233 ur hypothesis that adenosine, acting via the A1 receptor, in the basal forebrain is a key component i
234    This effect requires functional adenosine A1 receptors, in line with the observation that ATP is r
235 eceptor blockade in the presence of complete A1 receptor inhibition led to a reversible reduction of
236 .5 mM), but was not affected by an adenosine A1 receptor inhibitor, 8-cyclopentyl-1,3-dipropylxanthin
237 receptors and to decrease metabolic rate via A1 receptors inside the blood brain barrier.
238 me in the mammalian fetus that the adenosine A1 receptor is an important mediator of brain metabolic
239 oxygen consumption, suggesting the adenosine A1 receptor is involved in lowering metabolic rate durin
240 ing its cardioprotective effect, whereas the A1 receptor is linked via Gi to phospholipase C to produ
241 d indicate that LPA signaling through the LP(A1) receptor is required for normal development of an in
242  hypothesized that adenosine, acting via the A1 receptor, is a key factor in the homeostatic control
243 e is largely mediated by adenosine acting on A1 receptors, lead us to propose that adenosine is relea
244  3-kinase/AKT pathways primarily through the A1 receptor, leading to CASMC mitogenesis.
245 ccompanies sleep deprivation, acting via the A1 receptor, led to activation of the transcription fact
246 e include A2-receptor mediated vasodilation, A1-receptor mediated improvement of glycolysis during is
247 er, the cell-signaling mechanisms underlying A1 receptor-mediated CASMC proliferation in response to
248 rs with Cl-IB-MECA antagonized the adenosine A1 receptor-mediated inhibition of excitatory neurotrans
249  data provide good evidence for an adenosine A1 receptor-mediated inhibition of mAChR-mediated synapt
250  does not appear to be involved in adenosine A1 receptor-mediated inhibition of neuronal firing.
251 n addition, hydroxylamine reversed adenosine A1 receptor-mediated inhibition of the evoked population
252 ing extracellular adenosine, a loss of tonic A1 receptor-mediated inhibition.
253 n of a two-pore domain potassium channel and A1 receptor-mediated opening of a G-protein-coupled inwa
254 on and cardioprotection but had no effect on A1 receptor-mediated phospholipase C activation or cardi
255 h MRS 1191, which by itself had no effect on A1 receptor-mediated responses.
256 n increased both adenosine concentration and A1 receptor-mediated synaptic inhibition.
257                Agents that inhibit adenosine A1 receptors might be useful in the treatment of MTX-ind
258                                    Adenosine A1 receptors modulate baseline synaptic transmission in
259 e A1 receptor, this AAV-Cre markedly reduced A1 receptor mRNA and focally abolished the postsynaptic
260 s directly reduces tremor, whereas adenosine A1 receptor-null mice show involuntary movements and sei
261 the sign of Sema6D and signals Nr-CAM/Plexin-A1 receptors on RGCs to implement the contralateral RGC
262       However, during chemical ischemia, the A1 receptor pathway rapidly became ineffective.
263 tor was cloned and expressed in COS-1 cells, A1 receptor pharmacology is confirmed.
264  endogenous adenosine acting at the neuronal A1 receptor plays a major role in the depression of syna
265 ow that blocking the activation of adenosine A1 receptors prevents the long-term depression (LTD) evo
266 s study revealed a 3-fold RA-to-LA adenosine A1 receptor protein expression gradient in the human hea
267                                    Adenosine A1 receptor protein expression was significantly upregul
268 hese results show that presynaptic GABAB and A1 receptors reduce glutamate and GABA release from nerv
269 fect, but those for adrenergic and adenosine A1 receptors reduced firing.
270  that tonically released adenosine acting on A1 receptors reduces HR in 1CH rats and stimulates endot
271        We used CPA and DPCPX to test whether A1 receptors regulated spinal motor pattern generation i
272    In the presence of DPCPX (50 nM, to block A1 receptors), residual [125I]AB-MECA binding to A2A rec
273   Upon solubilization, the retinal adenosine A1 receptor retained binding characteristics similar to
274 e, because of its ability to block adenosine A1 receptors, shares neurochemical properties with other
275 dnSNARE mice) or pharmacological blockade of A1 receptor signaling using an adenosine A1 receptor (A1
276 ved intravitreal injections of the adenosine A1 receptor stimulant adenosine amine congener (ADAC) or
277  dose-dependent manner and predominantly via A1 receptors, stimulated IP3 receptor-regulated calcium
278 o indicate that muscle dilatation induced by A1 receptor stimulation is entirely NO dependent while t
279  KATP channel opening, while that induced by A1 receptor stimulation is wholly dependent on KATP chan
280     The selectivity level over the adenosine A1 receptor subtype for some of the more active analogue
281 aptic mechanisms involving the activation of A1 receptors suppress tremor activity and limit stimulat
282                             Antisense to the A1 receptor suppressed A1 receptor immunoreactivity but
283 ated by a pathway initiated at the adenosine A1 receptor that transduced signals through a Ca2+-activ
284 e results in elevated cell surface levels of A1 receptors, these cells will be more susceptible to ex
285 king the major coding exon for the adenosine A1 receptor, this AAV-Cre markedly reduced A1 receptor m
286 ting that adenosine signals strongly via the A1 receptor to these mitogenic signaling pathways.
287 ously released adenosine acts on endothelial A1 receptors to evoke dilatation in a NO-dependent fashi
288 ing systemic hypoxia and acts on endothelial A1 receptors to open KATP channels on the endothelial ce
289  mediated by adenosine acting at endothelial A1 receptors to stimulate synthesis and release of NO, w
290                     In chronic HF, adenosine A1 receptor upregulation in SAN pacemaker and atrial car
291 ain is unlikely to affect the sensitivity of A1 receptors via this mechanism.
292             When a cDNA encoding the porcine A1 receptor was cloned and expressed in COS-1 cells, A1
293 f a postsynaptic K+ conductance by adenosine A1 receptors was used to determine the rate of adenosine
294     As an example we show that the adenosine A1 receptor, when placed under the influence of the mous
295 sine may activate afferent discharge through A1 receptors, while sensitization to BK could involve a
296       Immature and mature synapses expressed A1 receptors with no observable difference in functional
297 potentiate agonist [(3)H]CCPA binding to the A1 receptor, with 4e as the best compound of the series.
298 ,273, which increases adenosine's binding to A1 receptors, would reduce hypoxia-induced brain injury.
299                                         This A1-receptor-Y(288)A was retained in the ER of stably tra
300 mbination and enhanced surface expression of A1-receptor-Y(288)A within 1 hour.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top